Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases: a pilot study.

Autor: Vija Racaru L; Department of Nuclear Medicine, Claudius Regaud Institute, Toulouse Oncology University Institute-IUCT-Oncopole.; Department of Biophysics and Nuclear Medicine, Faculty of Medicine, Paul Sabatier University.; INSERM U1037, Toulouse Oncology Research Centre (Centre de recherches en cancérologie de Toulouse, CRCT)., Sinigaglia M; Department of Nuclear Medicine, Claudius Regaud Institute, Toulouse Oncology University Institute-IUCT-Oncopole., Kanoun S; Department of Nuclear Medicine, Claudius Regaud Institute, Toulouse Oncology University Institute-IUCT-Oncopole., Ben Bouallègue F; Department of Nuclear Medicine, Toulouse University Hospitals, Toulouse, France., Tal I; IT Department, Beth Israel Deaconess Medical Center, Haifa, Israel., Brillouet S; Department of Nuclear Medicine, Claudius Regaud Institute, Toulouse Oncology University Institute-IUCT-Oncopole.; INSERM U1037, Toulouse Oncology Research Centre (Centre de recherches en cancérologie de Toulouse, CRCT)., Bauriaud-Mallet M; Department of Nuclear Medicine, Claudius Regaud Institute, Toulouse Oncology University Institute-IUCT-Oncopole.; INSERM U1037, Toulouse Oncology Research Centre (Centre de recherches en cancérologie de Toulouse, CRCT)., Zerdoud S; Department of Nuclear Medicine, Claudius Regaud Institute, Toulouse Oncology University Institute-IUCT-Oncopole., Dierickx L; Department of Nuclear Medicine, Claudius Regaud Institute, Toulouse Oncology University Institute-IUCT-Oncopole., Vallot D; Department of Nuclear Medicine, Claudius Regaud Institute, Toulouse Oncology University Institute-IUCT-Oncopole., Caselles O; Department of Nuclear Medicine, Claudius Regaud Institute, Toulouse Oncology University Institute-IUCT-Oncopole., Gabiache E; Department of Nuclear Medicine, Claudius Regaud Institute, Toulouse Oncology University Institute-IUCT-Oncopole., Pascal P; Department of Nuclear Medicine, Claudius Regaud Institute, Toulouse Oncology University Institute-IUCT-Oncopole.; Department of Nuclear Medicine, Toulouse University Hospitals, Toulouse, France., Courbon F; Department of Nuclear Medicine, Claudius Regaud Institute, Toulouse Oncology University Institute-IUCT-Oncopole.; Department of Biophysics and Nuclear Medicine, Faculty of Medicine, Paul Sabatier University.; INSERM U1037, Toulouse Oncology Research Centre (Centre de recherches en cancérologie de Toulouse, CRCT).; Department of Nuclear Medicine, Toulouse University Hospitals, Toulouse, France.

Publikováno v: Nuclear medicine communications [Nucl Med Commun] 2018 Jul; Vol. 39 (7), pp. 672-679.